BPC-157 (Body Protection Compound)

BPC-157 has demonstrated interesting properties in animal research — accelerated healing of tendons, ligaments, and intestinal tissue; anti-inflammatory effects; and gastroprotective properties. These findings have generated clinical interest. However, the majority of available data is from rodent studies, and controlled human clinical trials are limited. Extrapolating from animal studies to human clinical claims requires significant caution. This is why SPOKEmed evaluates BPC-157 use strictly on an individual, evidence-aware basis.

BPC-157 has been placed by the FDA on the Category 2 difficult-to-compound list, which restricts or prohibits its preparation by US compounding pharmacies for most uses. Regulatory status in this area evolves and should be verified at the time of any clinical decision. SPOKEmed stays current on FDA guidance affecting all peptides it considers offering and communicates regulatory reality transparently to patients.

Preclinical research in animal models has shown BPC-157 to have protective and reparative effects on gastric and intestinal mucosa, with studies demonstrating reduced inflammation and accelerated tissue healing in rodent models of inflammatory bowel disease and gastric ulcers. These findings are scientifically interesting and have generated clinical hypotheses. However, the translation from animal gut healing models to human clinical benefit has not been confirmed in published, controlled human trials. SPOKEmed does not recommend BPC-157 as a gut health treatment — for intestinal permeability and gut healing, SPOKEmed uses interventions with established human evidence: L-glutamine, zinc carnosine, butyrate, vitamin D, and GI-MAP-guided probiotic protocols.